CHICAGO, IL—Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients’ quality of life.
Almost 70% of healthy humans infected with more than 100 strains of human papillomavirus.
Oral HPV, HPV16 DNA commonly detected in patients with oropharyngeal cancer, but not their partners.
The FDA has approved Roche’s cobas HPV Test, the first human papillomavirus (HPV) DNA test for women ages >25 that can be used alone to help assess the need for additional diagnostic testing for cervical cancer.
Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus, specifically HPV 16 or 18.
Patients with HPV-positive OPSCC report different symptoms than those with HPV-negative OPSCC, which may have an effect on how early the disease is diagnosed.
Experts voted 13-0 that Roche’s test was safe and effective as first step in cervical cancer screening.
HPV vaccination is associated with reduced risk of atypic, atypia+ or cervical intraepithelial neoplasia grade 2 or 3.
The HPV vaccine protects against cancers of the cervix, throat, rectum, and penis, but too few girls and boys are getting vaccinated.
Three-year risks of CIN 2+ and CIN+ were 0.4% and 0.0%, respectively, after infection
